CompanySysmex Corp.
Japan
Sysmex is involved in the development, manufacture and sale of laboratory testing reagents and laboratory equipment; the development and sale of computer systems for medical institutions, as well as the development and sale of software used for clinical examination information systems. In addition, through its associated company, Sysmex is also engaged in the sale of extracorporeal diagnostic agents, as well as the import and sale of medical devices.
Private/Public:
public
Phone:+81 78 265 0500
Website:https://www.sysmex.co.jp/en/index.html
Address:1-5-1 Wakinohama-Kaigandori, Chuo-ku, Kobe, Hyogo 651-0073, Japan
Top Services
Product Groups
For Services/Products
API/Biologicals Production
API/Biologics development and manufacturing
Diagnostics
Diagnostic Testing Services - Genomic/Non-genomic
Medical and Delivery Devices
Diagnostic Equipment Offerings
Japan
- (12.May.2022) Sysmex Announces Changes from Financial Forecasts and Year-End Dividend for the Fiscal Year Ended March 31, 2022
- (12.May.2022) Declaration of Achieving Carbon Neutrality by 2040
- (02.May.2022) Astrego Diagnostics AB Becomes Wholly-Owned Sysmex Subsidiary Through the Acquisition of Outstanding Shares
- (04.Apr.2022) OGT Welcomes Adrian Smith as CEO
- (09.Mar.2022) Announcement of Organizational and Personnel Changes
- (15.Feb.2022) Sysmex Establishes Subsidiary in Saudi Arabia
- (26.Jan.2022) University of Chicago Clinical Trial Utilizes Sysmex Inostics Highly Effective HPV-SEQ Test to Measure HPV-DNA From Blood of Neck and Throat Cancer Patients
- (11.Jan.2022) Information About Termination of the Litigation Against Sysmex Corporation and Its Subsidiary
- (05.Jan.2022) Sysmex Files for Manufacturing and Marketing Approval for an Assay Kit That Assists in Identification of Amyloid Beta (Aβ) Accumulation in the Brain
- (23.Dec.2021) Sysmex and Yamato Transport Commence Dry Ice-Free Transportation of Reagents for Gene Testing in Consolidated Cargo at the Ultralow Temperature Range of Minus 70 Degrees Celsius
- (17.Nov.2021) Information About Litigation (Appeal) Against Sysmex Corporation and Its Subsidiary
- (10.Nov.2021) Announcement Regarding Differences Between Actual and Forecast Figures for the Six Months Ended September 30, 2021, and Revision of Full-Year Financial Forecasts
- (22.Oct.2021) Notice of Application for Selection of New Market Segment “Prime Market” on the Tokyo Stock Exchange
- (04.Oct.2021) Sysmex Launches Caresphere XQC, an External Quality Assessment App
- (01.Oct.2021) Sysmex Starts Implementing Job-Based HR Management System for All Employees
- (01.Oct.2021) Sysmex America Introduces First Hematology Analyzer for Malaria Detection: XN-30 Research Use Only Automated Hematology Analyzer
- (21.Sep.2021) Notice Concerning Absorption-Type Merger (Simplified/Short-Form Merger) of Wholly Owned Subsidiary
- (13.Sep.2021) Sysmex America, Inc. CEO Ralph Taylor to Retire
- (03.Sep.2021) Approval of "Genetic Diagnosis and Counseling for Inherited Retinal Dystrophy" Using Gene Panel Testing System for Advanced Medical Care B
- (25.Aug.2021) Information About Judgment of the Litigation Against Sysmex Corporation and Its Subsidiary
- (04.Aug.2021) OGT Expands Latest Support and Training Initiative with CytoCell University
- (01.Jul.2021) QIAGEN Forms Strategic Alliance With Sysmex Corporation for Global Cancer Companion Diagnostics Development and Commercialization Using NGS and Plasma-Safe-SeqS Technology
- (07.Jun.2021) Th2 Chemokine TARC Kit "HISCL TARC Assay Kit" is Approved for an Additional Indication as an Auxiliary for Assessment of COVID-19 Aggravation Risk